AID Clinical Trial

Abatacept In Juvenile Dermatomyositis

We are conducting a research study of an experimental biologic therapy Abatacept, administered by subcutaneous injection, for refractory juvenile dermatomyositis (JDM) (clinicaltrials.gov identifier NCT02594735). Pediatric and adult patients with JDM should have moderately active disease despite treatment with prednisone and at least one other medication. They must be at least seven years of age and weigh at least 66 lbs. to qualify for the study.

You may qualify if:
- You are an adult or child of at least seven years of age who has Juvenile Dermatomyositis (JDM).
- You have moderately active disease.
- You have had inadequate response or intolerance to prednisone and one other medication.
- You weigh at least 66 lbs.

Study details:
- Medical evaluations, study questionnaires, blood testing, and MRIs/x-rays will be performed at six visits over six months.
- No charge for study-related evaluations and testing.
- Travels funds and compensation available for study participants for five study visits after screening.
- If interested, please email hawal@mfa.gwu.edu or call 202.741.2389

Clinical Trial Team:
Hassan Awal, Clinical Research Coordinator
Dr. Rodolfo Curiel, Principal Investigator (rcuriel@mfa.gwu.edu)
Dr. Gulnara Mamyrova, Dr. Olcay Jones, Dr. Lisa Rider, Myositis Clinic

For more information:

hawal@mfa.gwu.edu
202.741.2389